MICHAEL HOLMAN: Open Payments
NPI 1073576070 · KOSCIUSKO, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$764 in 36 payments from 8 companies in 2025. Trend: 2023 $1,562 · 2024 $1,557 · 2025 $764
Food & beverage: $764
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $283 |
| Novo Nordisk Inc | 11 | $181 |
| PFIZER INC. | 5 | $92 |
| ABBVIE INC. | 4 | $65 |
| Otsuka America Pharmaceutical, Inc. | 2 | $60 |
| GlaxoSmithKline, LLC. | 2 | $32 |
| Averitas Pharma Inc. | 1 | $28 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $24 |
Products named: FARXIGA, Ozempic, BREZTRI, REXULTI, PREVNAR 20, Rybelsus, UBRELVY, NURTEC ODT.
Industry payments across MS — which companies pay providers there.
